Clinical trials: Primary Glaucoma
Glaucoma
Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate
This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently…
- Trial name
- NCT06730516
- Testing
- Latanoprost (Xalatan), Brimonidine 0.2 %
- Where
- Egypt
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy).
- Trial name
- NCT02406833
- Testing
- TGF-β2 antisense oligonucleotide, Trabeculectomy
- Where
- 3 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Isarna Therapeutics GmbH
Glaucoma, Open-Angle, Ocular Hypertension
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3…
- Trial name
- NCT01628601
- Testing
- Fixed combination 0.3 mg bimatoprost and 5 mg timolol
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Allergan
Primary Angle-Closure Glaucoma
Liwan Eye Study: the Fourth Follow-up
Primary angle-closure glaucoma (PACG) is one of the major causes of blindness affecting more than 20 million patients worldwide.
- Trial name
- NCT06333470
- Testing
- Primary angle closure diseases
- Volunteers
- 600 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Primary Open Angle Glaucoma, Glaucoma
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07076303
- Testing
- Direct Selective Laser Trabuloplasty
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brian Shafer
Primary Open Angle Glaucoma
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight…
- Trial name
- MAGIC (NCT05786196)
- Testing
- Ab-interno canaloplasty utilizing the iTrack Advance device, Ab-interno canaloplasty utilizing the OMNI Surgical System
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 86 people
- Sponsor
- Nova Eye, Inc.
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma (POAG), Istent Inject W
Trabecular Microbypass IStent in Patients with Glaucoma
The goal of this clinical trial is to assess the safety and efficacy of phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone in a Taiwanese population…
- Conditions
- Primary Open Angle Glaucoma (POAG), Istent Inject W, Normal Tension Glaucoma (NTG)
- Trial name
- NCT06630546
- Testing
- first generation iStent (Glaukos, San Clemente, CA, USA) insertion, phacoemulsification
- Where
- Taiwan
- Volunteers
- 71 people
- Sponsor
- Yu-Ting Tsao
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002.
- Trial name
- NCT02143843
- Testing
- Bimatoprost
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open Angle Glaucoma, Hypertension
Alternate Nostril Breathing Training in Geriatrics With Glaucoma and High Blood Pressure
Hypertension, particularly if poorly controlled, appears related to an increased risk of open angle glaucoma, (the high tension type of glaucoma is characterized as optic nerve degeneration with ocular hypertension).
- Trial name
- NCT05605743
- Testing
- breathing exercise
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Primary Open Angle Glaucoma
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with…
- Trial name
- NCT07235592
- Testing
- Microshunt XI
- Where
- 12 sites in Austria, Belgium and 6 more
- Volunteers
- 112 people
- Sponsor
- Santen SAS
Glaucoma
Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves
The purpose of this study is to evaluate and compare the clinical outcomes after implantation of the porous plate (polyethylene) (Model M4) Ahmed Glaucoma Valve with the silicone plate Ahmed Glaucoma Valve (Model FP7) in…
- Trial name
- NCT01883856
- Testing
- Silicone plate Ahmed Glaucoma Valve (Model FP7), Porous Plate Ahmed Glaucoma Valve (Model M4)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Peter Netland, MD
Primary Open Angle Glaucoma (POAG)
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients with POAG and indicated cataract surgery.
- Trial name
- NCT02434692
- Testing
- ARGOS-IO system
- Where
- 11 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma; Drugs
Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy
A 6-month, parallel-group study of the safety and efficacy of tafluprostin for Chinese patients with posttrabeculectomy residual primary angle-closure glaucoma or posttrabeculectomy residual primary open angle glaucoma.
- Trial name
- NCT03595865
- Testing
- tafluprostin
- Volunteers
- 60 people
- Sponsor
- wangdabo
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma
This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.
- Trial name
- RENOIR (NCT07617532)
- Testing
- Product DNN.31.19.026, COSOPT®
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.